Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA.
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1661-4. doi: 10.1016/j.bmcl.2010.01.072. Epub 2010 Jan 21.
A series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-one inhibitors of GSK3beta was developed from a low molecular weight, highly ligand efficient screening hit 1. Hit-to-lead optimization led to a number of highly potent inhibitors, while maintaining the high ligand efficiency of the screening hit.
开发了一系列 3-芳基-4-(芳腙基)-1H-吡唑-5-酮类 GSK3β 抑制剂,其先导化合物源于一个低分子量、高配体效率的筛选苗头化合物 1。从苗头化合物到先导化合物的优化得到了一些高效的抑制剂,同时保持了筛选苗头化合物的高配体效率。